What Is Pemvidutide? The Dual GLP-1/Glucagon Peptide Now in Phase 3 for MASH

Pemvidutide is one of the more interesting late-stage peptide therapies currently being studied because its development has moved beyond obesity alone and into serious liver disease.

It is an investigational once-weekly dual GLP-1 and glucagon receptor agonist peptide developed by Altimmune.

As of 2026, pemvidutide has entered Phase 3 development for metabolic dysfunction-associated steatohepatitis, or MASH, while also being studied in alcohol use disorder and alcohol-associated liver disease. (altimmune.com⁠)

What Is Pemvidutide?

Pemvidutide is an experimental peptide engineered to activate both:

• GLP-1 receptors
• glucagon receptors

Altimmune describes its receptor activity as approximately balanced 1:1 GLP-1/glucagon agonism. (altimmune.com⁠)

That balance is important because the two pathways contribute different effects.

GLP-1 activity is strongly associated with:

• reduced appetite
• satiety
• glucose regulation
• weight reduction

Glucagon receptor activity has more direct effects on:

• liver metabolism
• energy expenditure
• lipid metabolism
• hepatic fat handling

The aim is to combine these effects in one peptide.

How Is Pemvidutide Different From Standard GLP-1 Drugs?

Traditional GLP-1 receptor agonists primarily target the GLP-1 pathway.

Pemvidutide adds glucagon receptor activation.

This gives researchers a different therapeutic objective.

Rather than focusing mainly on appetite and weight, pemvidutide is designed to influence the liver directly while also producing systemic metabolic effects.

That makes it particularly relevant to conditions in which excess liver fat and inflammation play a major role.

What Is MASH?

MASH stands for metabolic dysfunction-associated steatohepatitis.

It is a more advanced form of metabolic fatty liver disease in which excess liver fat is accompanied by inflammation and cellular injury.

Over time, some people can develop:

• liver fibrosis
• cirrhosis
• liver failure
• increased cardiovascular risk

Because MASH is closely linked with obesity, insulin resistance and metabolic dysfunction, researchers are investigating therapies capable of addressing several of these processes simultaneously.

Why Might GLP-1/Glucagon Dual Agonism Help the Liver?

The proposed benefit comes from the complementary receptor effects.

GLP-1 activity may reduce:

• appetite
• calorie intake
• body weight

Glucagon receptor activity may directly influence:

• hepatic lipid metabolism
• fat oxidation
• energy expenditure

This creates the possibility of reducing liver fat both indirectly through weight loss and directly through liver metabolism.

That is one reason pemvidutide is being positioned primarily as a liver-disease treatment rather than simply another obesity drug.

What Did the Phase 2 MASH Trial Show?

The Phase 2b IMPACT trial investigated pemvidutide in people with MASH.

Altimmune reported that up to 58% of participants achieved MASH resolution without worsening of fibrosis at 24 weeks, compared with approximately 20% receiving placebo. (altimmune.com⁠)

Researchers also examined several non-invasive measures associated with liver inflammation and fibrosis.

These included:

• FibroScan liver stiffness
• ELF score
• MRI-PDFF
• ALT
• PRO-C3
• cT1 imaging

The overall pattern suggested improvements across several markers of liver health.

What Happened at 48 Weeks?

At 48 weeks, Altimmune reported continued improvement in multiple non-invasive fibrosis measures.

For example, the proportion of participants achieving both:

• at least a 0.5-point reduction in ELF
• and at least a 30% reduction in liver stiffness

was approximately:

• 27.8% with 1.2 mg pemvidutide
• 32.4% with 1.8 mg
• 3.2% with placebo

These findings supported progression into Phase 3. (altimmune.com⁠)

Has Pemvidutide Reached Phase 3?

Yes.

In August 2026, Altimmune initiated the PERFORMA Phase 3 trial.

PERFORMA is a global, randomised, double-blind, placebo-controlled study evaluating pemvidutide in people with MASH.

The trial is intended to serve as the company’s registrational Phase 3 programme for this indication. (ir.altimmune.com⁠)

Altimmune currently expects 52-week data from the programme in 2029.

Has Pemvidutide Received Any Regulatory Designations?

Yes.

The US FDA has granted pemvidutide:

• Fast Track designation for MASH
• Breakthrough Therapy designation for MASH
• Fast Track designation for alcohol use disorder

The Breakthrough Therapy designation was granted in January 2026 following review of the Phase 2 MASH data. (ir.altimmune.com⁠)

These designations do not mean the drug is approved.

They are designed to help accelerate development and regulatory review when preliminary evidence suggests potential benefit in a serious condition.

Is Pemvidutide Still Being Developed for Obesity?

Pemvidutide originally attracted considerable attention because of its effects on body weight.

However, Altimmune’s current development strategy is centred much more heavily on liver disease.

The company’s 2026 pipeline now prioritises:

• MASH
• alcohol use disorder
• alcohol-associated liver disease

rather than a standalone obesity programme. (altimmune.com⁠)

This is an important shift.

Why Move Away From Obesity Alone?

The obesity market has become extremely competitive.

Drugs targeting GLP-1, GIP, glucagon and amylin are now being developed by multiple major pharmaceutical companies.

Pemvidutide may have a more differentiated role in liver disease because glucagon receptor activation has direct metabolic effects within the liver.

That could give it a clearer niche than competing solely on weight reduction.

Is Pemvidutide Being Studied in Alcohol Use Disorder?

Yes.

This is one of the most unusual parts of the programme.

The Phase 2 RECLAIM trial investigated pemvidutide in 100 people with alcohol use disorder who also had overweight or obesity.

In July 2026, Altimmune reported that the study met its primary endpoint, showing a statistically significant reduction in heavy drinking days compared with placebo. (ir.altimmune.com⁠)

Secondary endpoints also included:

• reductions in WHO drinking-risk levels
• achieving zero heavy drinking days
• changes in phosphatidylethanol, or PEth

The FDA subsequently granted Fast Track designation for pemvidutide in alcohol use disorder.

Why Would a Metabolic Peptide Affect Alcohol Use?

This is an emerging area of research.

GLP-1 receptors are present in brain regions involved in:

• reward
• reinforcement
• appetite
• craving

Researchers are increasingly investigating whether GLP-1-related signalling can influence addictive behaviours, including alcohol consumption.

Pemvidutide’s GLP-1 activity may therefore contribute effects beyond conventional metabolic control.

This is still an experimental field.

What About Alcohol-Associated Liver Disease?

Pemvidutide is also being studied in alcohol-associated liver disease, or ALD.

The Phase 2 RESTORE trial has completed enrolment.

Altimmune expects topline results in the second half of 2027. (altimmune.com⁠)

This creates an interesting development strategy.

The same molecule is being studied for:

• metabolic liver disease
• alcohol-related behaviour
• alcohol-related liver injury

That is a relatively unusual clinical programme for a peptide originally associated with metabolic disease.

How Does Pemvidutide Compare With Survodutide?

Both activate:

GLP-1 + glucagon

But they are different molecules with different receptor balances and development strategies.

Survodutide is being developed heavily around obesity and metabolic disease.

Pemvidutide is now being positioned primarily around MASH and serious liver disease.

The mechanisms overlap, but their clinical priorities are diverging.

How Does Pemvidutide Compare With Retatrutide?

Retatrutide activates three receptors:

• GIP
• GLP-1
• glucagon

Pemvidutide activates two:

• GLP-1
• glucagon

Retatrutide therefore adds GIP activity.

But more receptors do not necessarily make one molecule better for every condition.

For liver disease, the balance between GLP-1 and glucagon signalling may be particularly important.

Does Pemvidutide Require Dose Titration?

One notable feature reported by Altimmune is that pemvidutide was administered without dose titration in its MASH programme.

Despite this, the company reported a generally favourable tolerability profile and a treatment-related discontinuation rate of around 1% in the IMPACT trial. (altimmune.com⁠)

That could become clinically relevant if confirmed in larger trials.

Many incretin-based treatments require gradual dose escalation to improve gastrointestinal tolerability.

What Are the Main Side Effects?

As with other GLP-1-related therapies, gastrointestinal effects remain an important consideration.

Early studies have reported events such as:

• nausea
• vomiting
• gastrointestinal discomfort

The full long-term safety profile will only become clearer as the Phase 3 programme progresses.

Is Pemvidutide a Peptide?

Yes.

Pemvidutide is a peptide-based dual receptor agonist.

Its structure incorporates technology designed to prolong its circulating half-life sufficiently for once-weekly administration. (altimmune.com⁠)

Is Pemvidutide Approved?

No.

Pemvidutide remains investigational.

It has not been approved by the FDA or other major regulatory authorities.

Phase 3 studies still need to confirm its effectiveness and long-term safety.

Why Is Pemvidutide Worth Watching?

Pemvidutide is interesting because its development path is becoming very different from many other metabolic peptides.

Rather than simply asking:

How much weight loss can this peptide produce?

researchers are asking whether the same mechanism can influence:

• liver inflammation
• liver fibrosis
• alcohol-related liver damage
• alcohol consumption
• metabolic dysfunction

That potentially gives pemvidutide a much broader therapeutic role.

The Bottom Line

Pemvidutide is an investigational once-weekly balanced GLP-1/glucagon dual receptor agonist peptide.

Its Phase 2 MASH programme reported MASH resolution without worsening fibrosis in up to 58% of participants, compared with 20% receiving placebo. (altimmune.com⁠)

Those findings led to FDA Breakthrough Therapy designation and the launch of the global PERFORMA Phase 3 trial in August 2026. (ir.altimmune.com⁠)

At the same time, positive Phase 2 findings in alcohol use disorder have opened another unexpected area of research.

Pemvidutide therefore represents an interesting evolution in peptide development:

from metabolic weight-loss research toward liver disease, fibrosis and even addiction-related biology.

For researchers following next-generation peptide therapeutics, that makes pemvidutide one of the more distinctive late-stage programmes to watch.

This article is for research and educational purposes only. Pemvidutide remains investigational and is not presented as an approved or established treatment.